SIGA Technologies, Inc. is an American

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympto ...

founded in 1995, currently based in

New York City New York, often called New York City or NYC, is the most populous city in the United States. With a 2020 population of 8,804,190 distributed over , New York City is also the most densely populated major city in the Un ...

, which develops and sells pharmaceutical solutions for the antiviral treatment of

smallpox Smallpox was an infectious disease caused by variola virus (often called smallpox virus) which belongs to the genus Orthopoxvirus. The last naturally occurring case was diagnosed in October 1977, and the World Health Organization (WHO) c ...

monkeypox Monkeypox (also called mpox by the WHO) is an infectious viral disease that can occur in humans and some other animals. Symptoms include fever, swollen lymph nodes, and a rash that forms blisters and then crusts over. The time from exposure t ...

cowpox Cowpox is an infectious disease caused by the ''cowpox virus'' (CPXV). It presents with large blisters in the skin, a fever and swollen glands, historically typically following contact with an infected cow, though in the last several decades more ...

, and vaccinia complications.

History

In September 2009, SIGA Technologies received a $1.6 million research fund from the

National Institutes of Health The National Institutes of Health, commonly referred to as NIH (with each letter pronounced individually), is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late ...

("NIH") for its broad-spectrum antiviral candidates. In August 2011, SIGA Technologies was awarded a $7.7 million grant from the

(NIH) to develop an antiviral drug for treating and preventing Lassa fever and others of

arenavirus An arenavirus is a bisegmented ambisense RNA virus that is a member of the family ''Arenaviridae''. These viruses infect rodents and occasionally humans. A class of novel, highly divergent arenaviruses, properly known as reptarenaviruses, have ...

origin. That year, it sealed a contract worth over $400 million to sell its antiviral drug TPOXX to the United States Biomedical Advanced Research and Development Authority (BARDA) for the purpose of its development and distribution. Also in 2011, it was ordered to pay $232 million in damages in a legal dispute with PharmAthene over rights to the smallpox drug tecovirimat. In July 2013, SIGA Technologies delivered about 590,000 courses of its smallpox antiviral drug

tecovirimat Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox. It is the first antipoxviral drug approved in the United States. It is an inhibitor of t ...

(Arestvy) to the United States Government's Strategic National Stockpile (SNS), meeting the requirement of Government's Biomedical Advanced Research and Development Authority (BARDA). In May 2018, the FDA advisory committee decided that the benefits of SIGA's small molecule antiviral treatment, TPOXX, outweigh its potential risks. Later in July, FDA granted the approval of TPOXX to SIGA after the drug was evaluated in 359 healthy human volunteers. In July 2019, SIGA signed a $23 million contract with the United States Department of Defense to create TPOXX's post-exposure prophylaxis. Tecovirimat was approved for medical use in the

European Union The European Union (EU) is a supranational political and economic union of member states that are located primarily in Europe. The union has a total area of and an estimated total population of about 447million. The EU has often been de ...

in January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. In 2021, SIGA submitted an intravenous version of TPOXX to the FDA for approval, which was approved in May 2022. In December 2021, Health Canada approved oral TPOXX for the treatment of smallpox in adults and pediatric patients weighing at least 13kg. In January 2022, the European Medicines Agency approved oral tecovirimat for smallpox, monkeypox, cowpox and vaccinia complications in adults and children with a body weight of at least 13kg. Intravenous (IV) TPOXX has no lower weight cap and can be used in infants under the Investigational New Drug protocol. The Centers for Disease Control and Prevention and FDA have relaxed regulations to make it easier for doctors in the United States to prescribe TPOXX to treat monkeypox patients.

Operations

SIGA has a well established cooperation with US federal agencies for its research and development activities. It provides countermeasures to the Strategic National Stockpile (SNS) and the

Department of Defense Department of Defence or Department of Defense may refer to: Current departments of defence * Department of Defence (Australia) * Department of National Defence (Canada) * Department of Defence (Ireland) * Department of National Defense (Philipp ...

(DoD), such as Category A pathogens using BSL-3 or -4 work. In September 2018, it signed a contract with BARDA for the delivery of oral and IV formulations of TPOXX to the Strategic National Stockpile, effective for the following years.

Products and services

SIGA's products include

, sold under the brand name TPOXX, the first drug approved by the FDA to treat adults and children for smallpox.

Recognition

In 2008, SIGA won its fourth listing on the Deloitte Tri-State Area Technology Fast 50, then at #44.

References

External links

* * {{Authority control Pharmaceutical companies established in 1995 Pharmaceutical companies of the United States Companies listed on the Nasdaq Publicly traded companies based in New York City